
Biotech Stocks Breaking News: Regeneron Gets Breakthrough Therapy Status
Regeneron Pharmaceuticals’ (REGN) shares were up 2.7% on the news that the FDA has granted Breakthrough Therapy designation to its eye drug Eylea, for the treatment of diabetic retinopathy in patients suffering from diabetic macular edema (DME). Breakthrough Therapy designation helps to accelerate the development and review process of experimental drugs that address an unmet medical need. The designation not only includes all of the … Continue reading Biotech Stocks Breaking News: Regeneron Gets Breakthrough Therapy Status